株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

西ナイルウイルス感染症:パイプライン製品の分析

West Nile Virus Infections - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 201011
出版日 ページ情報 英文 66 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
西ナイルウイルス感染症:パイプライン製品の分析 West Nile Virus Infections - Pipeline Review, H2 2017
出版日: 2017年09月19日 ページ情報: 英文 66 Pages
概要

西ナイルウイルス感染症は、蚊によって媒介されるウイルスによって引き起こされます。西ナイルウイルスは、フラビウイルスとして知られる、ウイルスの一種です。

当レポートでは、西ナイルウイルス感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

西ナイルウイルス感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

西ナイルウイルス感染症:企業で開発中の治療薬

西ナイルウイルス感染症:大学/機関で研究中の治療薬

西ナイルウイルス感染症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

西ナイルウイルス感染症:企業で開発中の製品

西ナイルウイルス感染症:大学/機関で研究中の製品

西ナイルウイルス感染症の治療薬開発に従事している企業

  • BioDiem Ltd
  • CalAsia Pharmaceuticals, Inc.
  • CEL-SCI Corporation
  • Kineta, Inc.
  • Nanotherapeutics, Inc.

西ナイルウイルス感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

西ナイルウイルス感染症:最近のパイプライン動向

西ナイルウイルス感染症:休止中のプロジェクト

西ナイルウイルス感染症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9738IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H2 2017, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.

West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide West Nile Virus Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • West Nile Virus Infections - Overview
    • West Nile Virus Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • West Nile Virus Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • West Nile Virus Infections - Companies Involved in Therapeutics Development
    • CEL-SCI Corp
    • Fab'entech SA
    • Hemispherx Biopharma Inc
    • Kineta Inc
    • Nanotherapeutics Inc
    • Plex Pharmaceuticals Inc
    • Theravectys SA
  • West Nile Virus Infections - Drug Profiles
    • AGS-v - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alferon LDO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BG-323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody for West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HydroVax-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-n3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tatbeclin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • West Nile Virus Infections - Dormant Projects
  • West Nile Virus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate
      • Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
      • May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
      • Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
      • Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
      • Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for West Nile Virus Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • West Nile Virus Infections - Pipeline by CEL-SCI Corp, H2 2017
  • West Nile Virus Infections - Pipeline by Fab'entech SA, H2 2017
  • West Nile Virus Infections - Pipeline by Hemispherx Biopharma Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Kineta Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Nanotherapeutics Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Theravectys SA, H2 2017
  • West Nile Virus Infections - Dormant Projects, H2 2017
  • West Nile Virus Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for West Nile Virus Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top